Showing results (471-480 of 523) with videos related to

Sort By:
Pageof 53
NPJ Precision Oncology|December 18, 2021
Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancerDiana Schaufler, David F Ast, Hannah L Tumbrink, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 25, 2019
Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO expertsPaul Martin Putora, Markus Glatzer, Dirk De Ruysscher, et al.
Molecular Cancer|October 4, 2024
Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX developmentDamien Vasseur, Ludovic Bigot, Kristi Beshiri, et al.
Lancet (London, England)|January 19, 2016
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)Fabrice Barlesi, Julien Mazieres, Jean-Philippe Merlio, et al.
European Journal of Cancer (Oxford, England : 1990)|March 16, 2020
The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical studyJean-Marie Michot, Ariane Lappara, Jérôme Le Pavec, et al.
The Lancet. Oncology|April 1, 2020
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trialJosé Trigo, Vivek Subbiah, Benjamin Besse, et al.
NPJ Precision Oncology|September 23, 2020
Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave RoussyGonzalo Recondo, Linda Mahjoubi, Aline Maillard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2022
Comprehensive Genome Profiling in Patients With Metastatic Non-Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 TrialFabrice Barlesi, Pascale Tomasini, Maryam Karimi, et al.
JCO Precision Oncology|March 2, 2023
Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid TumorsMihaela Aldea, Marco Tagliamento, Arnaud Bayle, et al.
Nature Cancer|February 4, 2022
Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expressionLucile Vanhersecke, Maxime Brunet, Jean-Philippe Guégan, et al.
Pageof 53